Wolchok, J. D. et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 40, 127–137 (2022).

Article  CAS  PubMed  Google Scholar 

Li, J. et al. KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19. Science 376, eabi9591 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chakraborty, S. et al. Providence of the CD25+KIR+CD127−FOXP3−CD8+ T cell subset determines the dynamics of tumor immune surveillance. Immunol. Cell Biol. 96, 1035–1048 (2018).

Article  CAS  PubMed  Google Scholar 

Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877–884 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature 596, 119–125 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliveira, G. et al. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature 605, 532–538 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lucca, L. E. et al. Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells. J. Exp. Med. 218, e20200921 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gueguen, P. et al. Contribution of resident and circulating precursors to tumor-infiltrating CD8+ T cell populations in lung cancer. Sci. Immunol. 6, eabd5778 (2021).

Article  CAS  PubMed  Google Scholar 

Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60–65 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yossef, R. et al. Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers. Cancer Cell 41, 2154–2165.e5 (2023).

Article  CAS  PubMed  Google Scholar 

Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22, 433–438 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pauken, K. E. et al. Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment. J. Exp. Med. 218, e20200920 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gros, A. et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246–2259 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Landa, B., Qu, R., Chang, J. & Kluger, Y. Local two-sample testing over graphs and point-clouds by random-walk distributions. Preprint at https://arxiv.org/abs/2011.03418 (2020).

Anfossi, N. et al. Coordinated expression of Ig-Like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells. J. Immunol. 173, 7223–7229 (2004).

Article  CAS  PubMed  Google Scholar 

Arlettaz, L., Degermann, S., Rham, C. D., Roosnek, E. & Huard, B. Expression of inhibitory KIR is confined to CD8+ effector T cells and limits their proliferative capacity. Eur. J. Immunol. 34, 3413–3422 (2004).

Article  CAS  PubMed  Google Scholar 

Yu, W. et al. Clonal deletion prunes but does not eliminate self-specific αβ CD8+ T lymphocytes. Immunity 42, 929–941 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koh, J.-Y., Kim, D.-U., Moon, B.-H. & Shin, E.-C. Human CD8+ T-cell populations that express natural killer receptors. Immune Netw. 23, e8 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Gimeno, L. et al. KIR+ CD8+ T lymphocytes in cancer immunosurveillance and patient survival: gene expression profiling. Cancers 12, 2991 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Filaci, G. et al. CD8+CD28− T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J. Immunol. 179, 4323–4334 (2007).

Article  CAS  PubMed  Google Scholar 

Kim, H.-J., Verbinnen, B., Tang, X., Lu, L. & Cantor, H. Inhibition of follicular T-helper cells by CD8+ regulatory T cells is essential for self tolerance. Nature 467, 328–332 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim, H.-J. et al. CD8+ T regulatory cells express the Ly49 Class I MHC receptor and are defective in autoimmune prone B6-Yaa mice. Proc. Natl Acad. Sci. USA 108, 2010–2015 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zabransky, D. J. et al. Phenotypic and functional properties of Helios+ regulatory T cells. PLoS ONE 7, e34547 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saligrama, N. et al. Opposing T cell responses in experimental autoimmune encephalomyelitis. Nature 572, 481–487 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhatt, R. S. et al. KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1. Cancer Immunol. Res. 9, 156–169 (2021).

Article  CAS  PubMed  Google Scholar 

Mathewson, N. D. et al. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell 184, 1281–1298.e26 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giles, J. R. et al. Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics. Nat. Immunol. 23, 1600–1613 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326–336 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013 e20 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).

Article  CAS